|
KIAA1549
|
0.400 |
Biomarker
|
disease |
CTD_human |
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma.
|
23817572 |
2013 |
|
KIAA1549
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Low-grade brain tumors (pilocytic astrocytomas) that result from a genomic rearrangement in which the BRAF kinase domain is fused to the amino terminal of the KIAA1549 gene (KIAA1549:BRAF fusion; f-BRAF) commonly arise in the cerebellum of young children.
|
23893969 |
2013 |
|
KIAA1549
|
0.400 |
Biomarker
|
disease |
BEFREE |
Search for KIAA1549:BRAF fusion in tumours with PA pattern is recommended even though the prognostic impact is still unclear.
|
23278243 |
2013 |
|
KIAA1549
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study supports the notion that BRAF duplication is more typical of posterior fossa pilocytic astrocytoma and that molecular alterations other than KIAA1549 fusion may underlie MAPK pathway activation in pilocytic astrocytoma of the optic nerve.
|
23702730 |
2013 |
|
KIAA1549
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
KIAA1549-BRAF fusion gene and isocitrate dehydrogenase (IDH) mutations are considered two mutually exclusive genetic events in pilocytic astrocytomas and diffuse gliomas, respectively.
|
22591444 |
2012 |
|
KIAA1549
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Chromosomal 7q34 duplication and BRAF-KIAA1549 fusion is a characteristic genetic alteration in pilocytic astrocytomas.
|
22568401 |
2012 |
|
KIAA1549
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Some of the molecular features are so specific to a particular type of tumors, such as the presence of the KIAA1549-BRAF fusion gene for pilocytic astrocytomas or SMARCB1 mutations for atypical teratoid/rhabdoid tumors, that they could practically serve as a diagnostic marker on their own.
|
23095836 |
2012 |
|
KIAA1549
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The frequency of BRAF-KIAA1549 fusion transcripts is significantly lower in adult patients with pilocytic astrocytoma, weakening the sensitivity of this specific diagnostic marker in that age group.
|
21696415 |
2011 |
|
KIAA1549
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further studies in larger RGNT case series are needed in order to demonstrate the possible presence of KIAA1549-BRAF fusion and better delineate its relationship with pilocytic astrocytomas.
|
21518014 |
2011 |
|
KIAA1549
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The data further support previous observations that these two alterations of the BRAF, KIAA1549 fusions and V600E point mutations, are associated primarily with pilocytic astrocytomas and nonpilocytic gliomas, respectively.
|
21884820 |
2011 |
|
KIAA1549
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies of genetic abnormalities in pediatric low-grade gliomas (LGGs) have focused on activation of the ERK/MAPK pathway by KIAA1549-BRAF gene fusions in the majority of pilocytic astrocytomas (PAs) and by rare mutations in elements of the pathway across histopathologically diverse LGGs.
|
21046410 |
2010 |
|
KIAA1549
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Different fusion variants involving BRAF and KIAA1549 were demonstrated, present in 80% of pilocytic astrocytomas in children.
|
20976706 |
2010 |
|
KIAA1549
|
0.400 |
Biomarker
|
disease |
BEFREE |
The latest discovery involving the tandem duplication and fusion BRAF-KIAA1549 on chromosome 7q34 in pilocytic astrocytoma has drawn attention to the MAPK-ERK pathway and its potential chemotherapeutic manipulation.
|
20919607 |
2010 |
|
KIAA1549
|
0.400 |
Biomarker
|
disease |
BEFREE |
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.
|
19363522 |
2009 |